CEL-SCI Corp (CVM) - Total Liabilities
Based on the latest financial reports, CEL-SCI Corp (CVM) has total liabilities worth $11.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CEL-SCI Corp (CVM) cash conversion ratio to assess how effectively this company generates cash.
CEL-SCI Corp - Total Liabilities Trend (1986–2025)
This chart illustrates how CEL-SCI Corp's total liabilities have evolved over time, based on quarterly financial data. Check CVM financial resilience to evaluate the company's liquid asset resilience ratio.
CEL-SCI Corp Competitors by Total Liabilities
The table below lists competitors of CEL-SCI Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greencore Group
LSE:GNC
|
UK | GBX780.70 Million |
|
Avicanna Inc
TO:AVCN
|
Canada | CA$9.86 Million |
|
Minrex Resources Ltd
AU:MRR
|
Australia | AU$178.64K |
|
Voyageur Pharmaceuticals Ltd
V:VM
|
Canada | CA$1.85 Million |
|
Eurobattery Minerals AB
F:EBM
|
Germany | €40.81 Million |
|
Orissa Bengal Carrier Limited
NSE:OBCL
|
India | Rs712.23 Million |
|
MODERN COMMERCE SA ZY-10
F:8F4
|
Germany | €22.85 Million |
|
TR Property Investment Trust plc
LSE:TRY
|
UK | GBX149.71 Million |
Liability Composition Analysis (1986–2025)
This chart breaks down CEL-SCI Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of CEL-SCI Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CEL-SCI Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CEL-SCI Corp (1986–2025)
The table below shows the annual total liabilities of CEL-SCI Corp from 1986 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $12.20 Million | -13.64% |
| 2024-09-30 | $14.12 Million | -18.42% |
| 2023-09-30 | $17.31 Million | -5.70% |
| 2022-09-30 | $18.36 Million | -5.04% |
| 2021-09-30 | $19.34 Million | -7.08% |
| 2020-09-30 | $20.81 Million | -7.47% |
| 2019-09-30 | $22.49 Million | -23.99% |
| 2018-09-30 | $29.59 Million | +12.66% |
| 2017-09-30 | $26.26 Million | +109.18% |
| 2016-09-30 | $12.55 Million | -39.29% |
| 2015-09-30 | $20.68 Million | +135.32% |
| 2014-09-30 | $8.79 Million | +112.33% |
| 2013-09-30 | $4.14 Million | -54.22% |
| 2012-09-30 | $9.04 Million | -5.31% |
| 2011-09-30 | $9.55 Million | -4.06% |
| 2010-09-30 | $9.95 Million | -73.24% |
| 2009-09-30 | $37.19 Million | +866.49% |
| 2008-09-30 | $3.85 Million | -36.52% |
| 2007-09-30 | $6.06 Million | -42.74% |
| 2006-09-30 | $10.58 Million | +971.99% |
| 2005-09-30 | $987.31K | +357.13% |
| 2004-09-30 | $215.98K | -87.22% |
| 2003-09-30 | $1.69 Million | -37.61% |
| 2002-09-30 | $2.71 Million | +433.57% |
| 2001-09-30 | $507.73K | -40.09% |
| 2000-09-30 | $847.42K | +69.48% |
| 1999-09-30 | $500.00K | +25.00% |
| 1998-09-30 | $400.00K | -20.00% |
| 1997-09-30 | $500.00K | +66.67% |
| 1996-09-30 | $300.00K | -81.25% |
| 1995-09-30 | $1.60 Million | +14.29% |
| 1994-09-30 | $1.40 Million | +100.00% |
| 1993-09-30 | $700.00K | +40.00% |
| 1992-09-30 | $500.00K | -28.57% |
| 1991-09-30 | $700.00K | +40.00% |
| 1990-09-30 | $500.00K | 0.00% |
| 1989-09-30 | $500.00K | -28.57% |
| 1988-09-30 | $700.00K | +133.33% |
| 1987-09-30 | $300.00K | -25.00% |
| 1986-09-30 | $400.00K | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more